Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non–small-cell lung cancer: A randomized trial

Jeremić, Branislav; Shibamoto, Yuta; Aćimović, Ljubiša; Miličić, Biljana; Milisavljević, Slobodan; Nikolic, Nebojsa; Dagović, Aleksandar; Aleksandrovic, Jasna; Radosavljevic-Asic, G.

doi:10.1016/s0360-3016(00)01546-7

Cited by 49 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…51 Eighteen trials clearly reported the number of participants randomised. [45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][61][62][63] All trials reported details of participant comparability at baseline.…”

Section: Qualitymentioning

confidence: 99%

“…Over 80% of patients were assessed in 18 trials. [45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][61][62][63] Fourteen trials [45][46][47][48][49][50][51][52][53][54][55][61][62][63] reported reasons for withdrawals, two trials 57,58 failed to report this and in three trials 56,59,60 there were no withdrawals. Six trials 46,48,51,54,59,61 used an ITT approach and assessed all participants according to the groups to which they were randomised.…”

Section: Qualitymentioning

confidence: 99%

“…Etoposide (ETOP) plus platinum (cisplatin or carboplatin) (PLAT) was used in seven trials. 49,50,56,57,[61][62][63] Radiation doses, number of fractions, schedule, relative dose intensity (RDI) and overall treatment time also varied between and within trials. Details of RDI are presented in Appendix 8.…”

Section: Trial Characteristicsmentioning

confidence: 99%

“…All but seven trials 49,51,53,54,56,60,61 specifically excluded pleural effusions (see Appendix 10). The majority of patients within each trial had either adenocarcinoma or squamous cell carcinoma, and three trials 46,48,63 failed to report details describing patient histology. In the majority of trials PS ranged from 0 to 1 [using a variety of PS criteria: ECOG, the Cancer and Leukemia Group B (CALGB) 48 , WHO] or from 60 to 100 (KPS).…”

Section: Patient Characteristicsmentioning

confidence: 99%

“…Two trials 62,63 comparing concurrent CTX-RT with concurrent CRX-RT were considered for inclusion in the meta-analysis on OS. None of the studies presented OS HRs data and therefore no meta-analysis was undertaken because it was impossible for the Assessment Group to estimate the OS HRs based on the published summary statistics.…”

Section: Concurrent Chemoradiation Compared With Concurrent Chemoradimentioning

confidence: 99%

See 4 more Smart Citations

Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review

Brown

Pilkington

Boland

et al. 2013

Health Technol Assess

View full text Add to dashboard Cite

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA programme findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'.For more information about the HTA programme please visit the website:

show abstract

Section: Qualitymentioning

confidence: 99%

Section: Qualitymentioning

confidence: 99%

Section: Trial Characteristicsmentioning

confidence: 99%

Section: Patient Characteristicsmentioning

confidence: 99%

Section: Concurrent Chemoradiation Compared With Concurrent Chemoradimentioning

confidence: 99%

See 3 more Smart Citations

Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review

Brown

Pilkington

Boland

et al. 2013

Health Technol Assess

View full text Add to dashboard Cite

show abstract

From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early‐stage nonsmall cell lung cancer

Jeremić

Miličić

2008

Cancer

View full text Add to dashboard Cite

2 ). Biologically equivalent doses for the 3 groups were 72 Gy, 78 Gy, and 76 Gy, respectively, for acute effects (a/b 5 10 Gy) and 120 Gy, 111 Gy, and 111 Gy, respectively, for late effects (a/b 5 2 Gy). RESULTS.For all 250 patients, the overall median survival was 27 months, the cause-specific survival was 27 months, the local progression-free survival was 32 months, and distant metastasis-free survival was not achieved; and the respective 5-year survival rates were 27%, 32%, 45%, and 68%. CF achieved significantly inferior survival than either HFX RT alone or HFX RT-Pac/C (P 5 .0332 and P 5 .0013, respectively), and no difference was observed between the 2 HFX RT regimens (P 5 .1934). Only acute hematologic high-grade toxicity (grade 3) was more frequent with HFX RT-Pac/C than with either RT alone, whereas other toxicities were similar between the 3 treatment groups.CONCLUSIONS. HFX RT with or without concurrent chemotherapy may be better than CF in patients with early-stage NSCLC. The role of chemotherapy deserves further investigation, because the group that received chemotherapy in the current study had a higher incidence of acute high-grade hematologic toxicity.

show abstract

Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy

Jeremić

Miličić

Milisavljević

2011

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Influence of potential clinical prognostic factors on overall survival (OS), local progression-free survival (PFS), and distant metastasis-free survival (MFS) in patients with locally advanced nonsmall cell lung cancer treated with hyperfractionated radiation therapy (HFX RT) with or without concurrent chemotherapy was investigated. METHODS: Three phase 3 and 2 phase 2 studies have been designed and executed with a total of 600 patients. HFX RT alone was given in 127 and HFX RT-chemotherapy was given in 473 patients. HFX RT doses were either 64.8 grays (Gy) or 69.6 Gy using 1.2 Gy twice daily, or 67.6 Gy using 1.3 Gy twice daily. Chemotherapy consisted of concurrent carboplatin and etoposide in 409 patients and concurrent carboplatin and paclitaxel in 64 patients. Sex, age, Karnofsky performance score (KPS), weight loss (>5%), stage, histology, interfraction interval, and treatment (the addition of concurrent chemotherapy) were investigated as potential prognostic factors. RESULTS: The median OS, median local PFS, and median distant MFS times were 19, 21, and 23 months, respectively. Five-year OS, local PFS, and distant MFS rates were 19%, 29%, and 35%, respectively. Univariate and multivariate analysis showed that only age did not influence OS and local PFS, whereas female sex, lower KPS, less pronounced weight loss, lower stage, squamous histology, shorter interfraction interval, and treatment independently predicted better OS and local PFS. Only age and treatment did not influence distant MFS, whereas histology was of borderline significance. CON-CLUSIONS: This study identified independent prognosticators of treatment outcome. These results may have implications for future studies in this disease.

show abstract

Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non–small-cell lung cancer: A randomized trial

Cited by 49 publications

References 33 publications

Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review

Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review

From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early‐stage nonsmall cell lung cancer

Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy

Contact Info

Product

Resources

About